3 weeks on tirzepatide no weight loss One month and 13 lbs down! Tirzepatide: My goal is to lose so I can exercise and be healthy. I am curvy, I will always be curvy and will always embrace Week 4 no weight-loss :

Appetite suppression via central nervous system GLP-1 receptors in appetite-regulating regions

Supporta la funzionalit mentale, migliorando concentrazione e memoria perch in grado di passare la barriera emato-encefalica

While its technically possible to combine sermorelin with Ipamorelin (since they act on different receptors), this isnt a standard protocol

Optimising injection technique: Allow medication to reach room temperature : Remove the pen from the refrigerator 30 minutes before injection to reduce discomfort Ensure proper needle insertion : Insert at a 90-degree angle with a swift, confident motion Rotate injection sites systematically : Use a different site each week and avoid injecting into areas that have not fully recovered Avoid injecting into areas with visible skin changes : Do not inject into bruised, scarred, inflamed or infected skin Use each pen only once : Tirzepatide pens are single-use devices and should be disposed of safely after one injection Pre-injection preparation: Clean the injection site with an alcohol wipe and allow it to dry completely before injecting (wet alcohol can cause stinging) Gently pinch the skin to create a subcutaneous fold, ensuring injection into fat rather than muscle Relax the injection areatense muscles can increase discomfort Post-injection care: Apply gentle pressure with clean gauze if minor bleeding occurs, but avoid rubbing the site A cool compress (not ice directly on skin) can reduce swelling and discomfort Avoid tight clothing over the injection site for several hours Monitor the site for 2448 hours for any worsening symptoms Symptomatic relief: For mild itching or discomfort, over-the-counter oral antihistamines (such as cetirizine) may provide relief, though patients should consult their pharmacist or GP before starting any new medication to check for potential interactions or contraindications

Characteristics of elderly patients initiating sitagliptin or non-DPP-4-inhibitor oral antihyperglycemic agents: analysis of a cross-sectional US claims database